Overview

Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

Status:
Active, not recruiting

Trial end date:
2022-03-25

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic, and immunogenic profiles of satralizumab, compared with placebo, in addition to baseline immunosuppressive treatment in participants with NMO and NMOSD.

Phase:

Phase 3

Details

Lead Sponsor:

Chugai Pharmaceutical
Hoffmann-La Roche

Collaborator:

Chugai Pharmaceutical